HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms
Preprint
Kumar P. et al, (2024)
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Journal article
Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial.
Journal article
Freeman SD. et al, (2023), Blood, 142, 1697 - 1707
Changing treatment changing prognosis of mutations
Journal article
Vyas P., (2023), Blood, 142, 1583 - 1585
A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.
Journal article
Turkalj S. et al, (2023), STAR Protoc, 4
Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging
Preprint
Jakobsen NA. et al, (2023)
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
Journal article
Daver NG. et al, (2023), J Clin Oncol
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Journal article
Lachowiez CA. et al, (2023), Blood Cancer Discov, 4, 276 - 293
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Dataset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Dataset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies
Fileset
Lachowiez CA. et al, (2023)
An Overview of Targeted Therapies in Acute Myeloid Leukemia.
Journal article
Turkalj S. et al, (2023), Hemasphere, 7
Phenotypic screening identifies a trisubstituted imidazo[1,2-a]pyridine series that induces differentiation in multiple AML cell lines.
Journal article
Josa-Culleré L. et al, (2023), Eur J Med Chem, 258